ACD
Boulder City, Colorado, United States
ACD
Boulder City, Colorado, United States

Time filter

Source Type

OTTAWA, May 01, 2017 (GLOBE NEWSWIRE) -- Aujourd’hui, c’est le Lundi du mélanome et l’Association canadienne de dermatologie (ACD) retourne sur la Colline pour offrir aux députés et aux sénateurs sa séance annuelle de dépistage du cancer de la peau. La séance de dépistage sur la colline du Parlement est coparrainée par Geoff Regan, président de la Chambre des communes, et Bill Casey, député de Cumberland-Colchester, et organisée par l’ACD. Il y a quelques années, M. Casey avait reçu un diagnostic de mélanome à l’occasion d’une séance de dépistage tenue sur la colline du Parlement, ce qui lui avait permis de recevoir rapidement un traitement et de combattre la maladie avec succès. L’événement en question avait été parrainé par Mme Dona Cadman, veuve du député Chuck Cadman, décédé d’un mélanome. Outre la détection précoce de cas de cancer, la séance de dépistage vise à sensibiliser les parlementaires aux signes du cancer de la peau et à leur faire connaître les mesures de prévention, qui sont toutes simples. Le dépistage et le traitement précoces du mélanome, du cancer basocellulaire et du cancer spinocellulaire permettent de réduire la gravité des cicatrices résultant du traitement et même, dans le cas du mélanome, de prévenir le décès. Pour réduire encore davantage les risques de cancer de la peau, il faut aussi éviter les pratiques dangereuses comme le bronzage artificiel. L’incidence du mélanome est à la hausse, tant chez les hommes que chez les femmes, depuis quelques décennies, le taux d’augmentation ayant atteint 2,4 % par année chez les hommes entre 2001 et 2010, et 2,8 % par année chez les femmes entre 2004 et 2010. L’exposition aux rayons ultraviolets (UV) du soleil, des lits de bronzage et des lampes solaires semble être le principal facteur de risque de mélanome. Le nombre et le type de grains de beauté, la peau claire, les antécédents familiaux de cancer de la peau, un système immunitaire affaibli et une histoire de coups de soleil graves avec cloques, sont parmi les autres facteurs de risque. Au sujet de l’ACD L’Association canadienne de dermatologie, fondée en 1925, représente les dermatologues du Canada. L’Association offre un accès facile à la source la plus importante et la plus fiable de savoir médical en dermatologie. L’ACD a pour mission de faire avancer la science et l’art de la médecine et de la chirurgie dans le domaine des soins de la peau, des cheveux et des ongles, d’offrir du perfectionnement professionnel continu à ses membres, d’appuyer et d’améliorer les soins aux patients, de sensibiliser le public à la protection solaire et aux autres aspects de la santé de la peau et de promouvoir la santé de la peau, des cheveux et des ongles, la vie durant. Ce faisant, l’ACD informe et habilite aussi bien les professionnels de la médecine que le public canadien.


OTTAWA, May 01, 2017 (GLOBE NEWSWIRE) -- Des membres du Conseil d’administration de l’ACD et des dermatologues et résidents en dermatologie de la région d’Ottawa offriront une séance de dépistage du cancer de la peau aux députés et sénateurs et leur apprendront comment on peut effectuer soi-même un examen de la peau à la maison. L’événement est organisé dans le cadre du Programme de prudence au soleil de l’Association canadienne de dermatologie.


News Article | May 2, 2017
Site: www.prnewswire.com

The company's financial statements are prepared in accordance with accounting principles generally accepted in the United States (GAAP). Adjusted EPS, adjusted earnings, adjusted gross margin, adjusted operating income, and adjusted operating margin are non-GAAP measures that exclude certain items detailed later in this press release under the heading "Use of Adjusted Financial Measures." A reconciliation of GAAP to non-GAAP financial measures is included in this press release. "My compliments to our global teams for a solid quarter with organic growth in the mid-single digits, led by Europe with organic growth in the upper-teens, a record for us," said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne.  "We have many highlights to discuss this quarter including a return to growth in Japan and strong 20% growth in Protein Platforms.  ACD also continues to surprise us, with growth nearing 60%, well on its way to surpassing the milestones we gave the team for the final earn-out payment this December." Kummeth added, "However, timing of orders in our Diagnostics segment is still impacting overall Company quarterly growth rates. No business has been lost in this division, but an emphasis on inventory metrics by its large Dx customer base has pushed out some deliveries into next fiscal year. Longer term, the pipeline of new business for this division looks stronger than ever." Kummeth concluded, "With the ongoing integration of the nine acquisitions we have done over the past 3.5 years, our focus has been on maintaining high margins along with revenue growth.   With our latest acquisition, ACD, now absorbed into Bio-Techne's operating processes, our adjusted operating margins continue to improve.   True to our word, our adjusted operating margins in Q3 increased sequentially by over 200 basis points from Q2.  My thanks to our employees worldwide, now totaling near 1800, for the wonderful execution." Net sales for the third quarter increased 10% to $144.0 million. Organic growth was 4% compared to the prior year, with currency translation having a negative impact of 2% and acquisitions contributing 8% to revenue growth. GAAP EPS decreased to $0.57 per diluted share, versus $0.81 in the same quarter last year. GAAP operating income for the third quarter of fiscal 2017 decreased 26% to $32.3 million, compared with $43.5 million in the third quarter of fiscal 2016.  GAAP operating margin was 22.4%, compared with 33.2% in the third quarter of fiscal 2016. GAAP operating margin compared to prior year was negatively impacted by additional expenses associated with the acquisitions made in fiscal 2017. These expenses include selling, general and administrative expenses, acquisition intangible amortization, contingent consideration fair value adjustments, and other acquisition costs. GAAP diluted EPS was also negatively impacted by higher interest costs associated with the financing of recent acquisitions. Adjusted EPS decreased to $0.97 per diluted share, versus $1.01 in the same quarter last year. Adjusted operating income for the third quarter of fiscal 2017 decreased 3% compared to the same quarter last year. Adjusted operating margin was 37.3%, compared with 42.4% in the third quarter of fiscal 2016. Adjusted operating margin compared to prior year was negatively impacted by the mix of lower-margin acquisitions made in fiscal 2017. Adjusted EPS was negatively impacted by higher interest costs associated with the financing of recent acquisitions and benefitted from a lower adjusted effective income tax rate due to geographic mix. Management uses adjusted operating results to monitor and evaluate performance of the Company's three business segments, as highlighted below.  Since these results are used for this purpose, they are also considered to be prepared in accordance with GAAP. The Company's Biotechnology segment includes proteins, antibodies, immunoassays, flow cytometry products, intracellular signaling products, and biologically active chemical compounds used in biological research. Biotechnology segment's third quarter fiscal 2017 net sales were $94.5 million, an increase of 16% from $81.4 million for the third quarter of fiscal 2016. Organic growth for the segment was 6%, with currency translation having an unfavorable impact of 2% on revenue growth and acquisitions contributing 12% to revenue growth. Biotechnology segment adjusted operating margin was 47.9% in the third quarter of fiscal 2017 compared to 55.5% in the third quarter of fiscal 2016. The lower operating margin is largely the result of recent acquisitions, namely ACD, made in this segment. The Company's Protein Platforms segment develops proprietary systems and consumables for protein analysis. In the third quarter of fiscal 2017, segment revenue was $23.6 million, an increase of 20% from $19.7 million for the third quarter of fiscal 2016.  Organic growth for the segment was 20% with currency translation having an unfavorable impact of 2% and acquisitions contributing 1%. The Protein Platforms segment's adjusted operating margin was 13.8% in the third quarter of fiscal 2017 compared to 8.1% in the third quarter of fiscal 2016. The higher segment operating margin was primarily the result of volume leverage. The Company's Diagnostics segment provides a range of controls and calibrators for various blood and blood chemistry clinical instruments, as well as quality controls, diagnostic immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics segment's third quarter fiscal 2017 net sales were $26.0 million, a decrease of 13% (all organic) compared to the third quarter of fiscal 2016. The Diagnostics segment's adjusted operating margin was 23.1% in the third quarter of fiscal 2017 compared to 31.6% in the third quarter of fiscal 2016. The lower operating margins were driven by a lower volume leverage and margin mix of product sales. Bio-Techne will host an earnings conference call today, May 2, 2017 at 8:00 A.M. Central time. To listen, please dial (877) 879-6203 or (719) 325-4749 for international callers. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call. The replay will be available from 11:00 P.M. Central time on Tuesday, May 2, until 5:00 P.M. Central time on Friday, June 2, 2017. To access the replay please go to: http://audio.viavid.com/20170502-123977-bio-techne.mp3 Use of Adjusted Financial Measures: This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include: We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results. Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, and acquisition related expenses.  The Company excludes amortization of purchased intangible assets and purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses, from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure.   Additionally, these amounts can vary significantly from period to period based on current activity. The Company's non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes stock based compensation expense and certain adjustments to income tax expense.  Stock based compensation is excluded from non-GAAP adjusted earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, and the variety of award types.  The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments.  In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings.  We believe these tax items can significantly affect the period-over period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results. Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release. Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships. For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements. Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota. The Protein Platforms Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $499 million in net sales in fiscal 2016 and has approximately 1,700 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/bio-techne-releases-third-quarter-fiscal-2017-results-300449194.html


News Article | February 15, 2017
Site: www.prweb.com

Noble Systems Corporation, a global leader in omnichannel contact center technology solutions, is pleased to announce that Dollar UK have seen dramatic improvements to their contact center key metrics following implementation of the Noble® Enterprise Cloud Solution. Dollar UK, a leading provider of consumer finance, selected Noble Systems because they offered a true vendor partnership to support the company’s expansion plans. Dollar UK were unable to meet their business objectives with their incumbent supplier. Since implementing the Noble Cloud Solution they have seen several improvements, including the following key metrics: “We chose Noble Systems to future proof our investment,” said Mike Blomfield, Chief Information Officer (CIO), Dollar UK. “We were looking for the right platform that could be implemented rapidly, with advanced functionality that could improve productivity and help us provide better customer service. We found Noble to be a flexible and helpful partner right from the beginning of the contract.” Dollar UK has also seen improvements in efficiency with a single point for monitoring, call recording and real-time reporting. The Noble solution allows for rapid ad-hoc dialing campaigns, which means that the Dollar UK managers are now able to create new campaigns and have them up and running within an hour. “Noble Systems and Dollar UK are a great example of a true customer/vendor partnership,” said Chris Hodges, Senior VP Sales and Marketing for Noble Systems. “We are proud to support Dollar UK on their ongoing journey and are delighted to hear of the incredible improvements in their key metrics.” About Noble Systems Noble Systems Corporation is a global leader in the customer communications industry, providing innovative solutions for Contact Center, Workforce Management, and Analytics technologies. Tens of thousands of agents at 4,000+ client installations worldwide use Noble platforms to manage millions of customer contacts each day. Noble offers a unified suite of inbound, outbound, and omnichannel contact processing, strategy planning, resource management, and compliance tools for companies of all sizes. Our premise, cloud, and innovative premise/cloud hybrid platforms include ACD, predictive dialing, blended processing, recording and monitoring, IVR, messaging, interaction analytics, and workforce management. For more information, contact Lee Allum at 1.888.8NOBLE8 or visit http://www.noblesystems.com. About Dollar UK Dollar UK is a leading provider of consumer finance, running brands such as The Money Shop and Payday UK. The Money Shop is a provider of financial services to a wide range of customers nationwide. Products include loans, pawnbroking, gold to cash, travel money, retail jewelry, and check cashing. The Money Shop online is a platform that allows easy access to a variety of Money Shop products including a range of short terms loans. Websites: http://www.dollaruk.com | http://www.themoneyshop.com.


News Article | February 23, 2017
Site: www.prweb.com

Noble Systems, a global leader in omnichannel contact center technology solutions, announces that ethical fundraising services specialist Smart Health Australia has selected the Noble® Enterprise Cloud solution to optimize fundraising center performance and support organizational development. “Technology is a pivotal factor in the success of the modern fundraising organization. Our agents and management personnel need to be using advanced, analytical omnichannel tools with an established reputation of reliability,” said Michael Copsey, IT Director, Smart Health Australia. "We chose Noble because their cloud solution is proven to get the job done and offers the flexibility, interoperability via API’s and scalability to support our growth and client needs.” Smart Health’s agents will be using Noble Enterprise Cloud to help maximize ROI for the charities with which the company works. The solution allows Smart Health to minimize costs and maintenance responsibilities, gives them the ability for agents to work-from-home, and creates an environment for greater agent availability and operational flexibility. It also enables Smart Health to improve campaign management by running multiple campaigns on a single platform, strengthen quality assurance with advanced interaction recording and monitoring tools, and increase right party donor contacts with blended inbound/outbound contact processing technology – in a cloud-based package with industry-leading reliability. “It is clear from Smart Health’s investment in donor contact technology that the organization is committed to providing its agents with the means to perform at their optimal ability,” said Chris Hodges, Senior Vice-President Sales & Marketing, Noble Systems. “Noble Cloud is a solution that will expand as Smart Health‘s needs evolve, while sustaining unmatched dependability.” About Noble Systems Noble Systems Corporation is a global leader in the customer communications industry, providing innovative solutions for Contact Center, Workforce Management, and Analytics technologies. Tens of thousands of agents at 4,000+ client installations worldwide use Noble platforms to manage millions of customer contacts each day. Noble offers a unified suite of inbound, outbound and blended omnichannel communications, strategy planning, resource management, and compliance tools for companies of all sizes. Our premise, cloud, and hybrid platforms include ACD, predictive dialing, blended processing, recording and monitoring, IVR, messaging, regulatory compliance, interaction analytics, and workforce management. For more information, contact Lee Allum at 1.888.8NOBLE8 or visit http://www.noblesystems.com. About Smart Health Australia Smart Health Australia have built a formidable reputation over twenty years of operation helping non-profit organizations raise funds to assist those most in need. Headquartered in Melbourne, Australia, Smart Health provide telemarketing and consultative services to leading organizations involved in delivering better community outcomes and saving lives. The award winning fundraising specialist is committed to the highest professional and ethical standards. Smart Health Australia deliver tailor-made fundraising campaigns focused on enhancing donor loyalty, retention, and building long-term donor relations while increasing the charities’ fundraising revenue. http://www.sha.net.au


News Article | February 21, 2017
Site: www.prweb.com

Noble Systems Corporation, a global leader in omnichannel contact center technology solutions, announces the issuance of a US Patent for the company’s exclusive SmartAccept™ technology. SmartAccept helps inbound call centers and service organizations shrink Average Seconds to Answer (ASA), decrease abandoned calls, and deliver a better customer experience. Noble’s SmartAccept™ technology has been issued patent #9,560,210 entitled “Telephone Call Processing Modifications Related to Call Acceptance for an Incoming Call Received at a Contact Center.” SmartAccept allows companies to reduce hold times, even before they answer a call, making an intelligent decision on whether to answer the call immediately or continue to ring the line based on agent availability. By substantially decreasing hold times, companies can improve key service levels and increase customer satisfaction while lowering their telecom costs. “By simply adding as few as four rings, SmartAccept can eliminate 24 seconds of hold time for the customer,” said Jim Noble, President and CEO of Noble Systems. “Recent studies show that the average business hold time is over 50 seconds. SmartAccept cuts that hold time almost in half – significantly reducing the time to answer and providing a better overall experience. And if the impact on ASA and critical service indicators isn’t convincing enough, it also eliminates 24 seconds of telecom costs per call. It’s time to get smart about inbound call management.” About Noble Systems Noble Systems Corporation is a global leader in the customer communications industry, providing innovative solutions for Contact Center, Workforce Management, and Analytics technologies. Tens of thousands of agents at 4,000+ client installations worldwide use Noble platforms to manage millions of customer contacts each day. Noble offers a unified suite of inbound, outbound, and omnichannel contact processing, strategy planning, resource management, and compliance tools for companies of all sizes. Our premise, cloud, and innovative premise/cloud hybrid platforms include ACD, predictive dialing, blended processing, recording and monitoring, IVR, messaging, interaction analytics, and workforce management. For more information, contact Lee Allum at 1.888.8NOBLE8 or visit http://www.noblesystems.com.


News Article | February 15, 2017
Site: www.prweb.com

ACD, a leading claims technology, decision support, advisory and service network aggregator to the property and casualty industry today announced a key enhancement to the company’s flagship material damage workflow platform AutoLink®. Through ACD’s advanced proprietary algorithms, AutoLink’s Predictive Scoring Solution™ (PSS) can now help insurers identify potential total losses and recommend early tow opportunities to dramatically lower cycle times and expenses, all which assist adjusters in closing files faster and more efficiently. “Our technology team has been at the forefront of predictive data for years with our intelligent dispatching and method of inspection routing solutions. Now, our Predictive Scoring Solution™ is yet another leap forward,” stated ACD CEO, Ernie Bray. “Modern insurers in today’s rapidly changing claims environment need more than just a platform - they need technology that provides feedback and recommendations in real time to allow for quick and decisive assessments. Our ability to consistently deliver results has led to many insurers adopting our integrated workflow platform,” added Bray. ACD’s process of continuously developing customizable modules has provided insurers nationwide with solutions that can support their unique workflows. In an era of connectivity and rapid change, ACD's AutoLink® claims workflow platform is a market leader in innovation that connects and unifies a fragmented auto insurance claims industry with digitally empowered solutions. ACD, an award-winning company, has been ranked four years on Deloitte's Technology Fast-500 of North America and six times on the INC. 5000. ACD's technology and claims service group has processed over $3B in claims, smoothing the way for insurers and their customers. ACD is a leading technology firm located in Carlsbad. For more information visit ACD http://www.acdcorp.com


News Article | February 15, 2017
Site: www.prweb.com

Aimetis Corp., a global leader in intelligent video management software (VMS), today announced the release of two new analytics for the Axis Camera Application Platform (ACAP). As part of the growing Aimetis suite of embedded video analytics, Aimetis Motion Tracker (AMT) and Aimetis Crowd Detection (ACD) deliver added functionality and value to Axis network cameras and encoders. The new applications can be used with Aimetis Symphony™ VMS, reducing the CPU load of the server, or with any 3rd party VMS which supports the Axis Event Data-Streaming API. AMT reliably tracks changes in dynamic surroundings and can be configured using the embedded rule engine to alarm on custom events such as tripwire and alarm zone violations. It goes beyond standard motion detection by locating and tracking movement across multiple video frames. By distinguishing changes between frames, AMT can alarm on object direction and be used in combination with video management software to run searches and reports. “Aimetis Motion Tracker provides more value than traditional video motion detection by reliably capturing object location and streaming detailed metadata to a VMS,” said Justin Schorn, VP Product Management at Aimetis. “This is superior to the included motion detection capabilities on the camera, which have limited integration possibilities. Previously only available through Aimetis Symphony™ as a server-based add-on, Aimetis Crowd Detection (ACD) is now available as a standalone analytic application that can be installed on Axis cameras. ACD can be used to monitor public spaces by determining sudden congregations in areas of interest. It also monitors occupancy levels to identify bottlenecks and overcrowding for several different verticals, including retail, entertainment, and government. “Monitoring occupancy levels is important for both public safety, and optimizing staff deployment,” said Justin Schorn, VP Product Management at Aimetis. “Aimetis Crowd Detection will help surveillance systems become more proactive and reduce risk, without the need to upgrade any server hardware.” About Aimetis Aimetis, a Senstar company, simplifies the management of network video for security surveillance by offering smart solutions with the lowest total cost of ownership for our connected world. Combining an industry leading video management system with integrated analytics and centralized management in the cloud, Aimetis delivers the most scalable and easiest to use video management platform on the market. Founded in 2003, Aimetis has established itself as a global leader in intelligent video management from its headquarters in Waterloo, Canada. Aimetis has distributors and certified partners in over 100 countries and serves a variety of industries, including retail, transportation, and others.


News Article | February 15, 2017
Site: www.prweb.com

Carlsbad based ACD, a leading claims technology, decision support, advisory and service network aggregator to the property and casualty industry today announced the opening of its new corporate headquarters in Carlsbad, California. ACD is experiencing rapid growth after ending a year which again saw the company being named for the sixth time to Inc. 5000’s “America’s Fastest-Growing Private Companies” list and honored as one of the “Best Entrepreneurial Companies in America” by Entrepreneur Magazine. “Our company has experienced amazing growth and we’ve quickly outgrown our current facility. I’m very excited for our move into the new headquarters which will enable us to add even more great team members,” stated Brian Bray, Vice President of Operations. “We will be expanding staff in Carlsbad as we enter a new phase in our accelerated growth. The additional space will allow for further innovation and expansion of our technology R&D programs centered on future-based software solutions for the property & casualty industry. We’re looking forward to making 2017 a great year for our clients as we continue on our mission to be the company of choice for insurers who want a modern solution that drives their success,” added Bray. In an era of connectivity and rapid change, ACD's AutoLink® claims workflow platform is a market leader in innovation that connects and unifies a fragmented auto insurance claims industry with digitally empowered solutions. ACD, an award-winning company, has been ranked four years on Deloitte's Technology Fast-500 of North America and six times on the INC. 5000. ACD's technology and claims service group has processed over $3B in claims, smoothing the way for insurers and their customers. ACD is a leading technology firm located in Carlsbad. For more information visit ACD http://www.acdcorp.com


News Article | February 23, 2017
Site: www.businesswire.com

Die Analyse zeigt eine klare Abhängigkeit zwischen verwendetem Codec und durchschnittlicher Gesprächsdauer (ACD). Überraschenderweise findet die Studie, dass auch ein Grad von Paketverlust und Jitter, der typischerweise in „Voice over LTE“- und „Voice over Wifi“-Netzen auftritt, schon substanziellen Einfluss auf die Gesprächsdauer hat.

Loading ACD collaborators
Loading ACD collaborators